Related Experiment Video
Updated: Jun 6, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that
Thomas Kruewel1, Silvia Schenone, Marco Radi
1Center for Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany.
Background:
The non-receptor tyrosine kinases c-Abl and c-Src are overexpressed in various solid human tumours. Inhibition of their hyperactivity represents a molecular rationale in the combat of cancerous diseases. Here we examined the effects of a new family of pyrazolo [3,4-d] pyrimidines on a panel of 11 different murine lung tumour progenitor cell lines, that express stem cell markers, as well as on the human lung adenocarcinoma cell line A549, the human hepatoma cell line HepG2 and the human colon cancer cell line CaCo2 to obtain insight into the mode of action of these experimental drugs.
Methodology/Principal Findings:
Treatment with the dual kinase inhibitors blocked c-Abl and c-Src kinase activity efficiently in the nanomolar range, induced apoptosis, reduced cell viability and caused cell cycle arrest predominantly at G0/G1 phase while western blot analysis confirmed repressed protein expression of c-Abl and c-Src as well as the interacting partners p38 mitogen activated protein kinase, heterogenous ribonucleoprotein K, cyclin dependent kinase 1 and further proteins that are crucial for tumour progression. Importantly, a significant repression of the epidermal growth factor receptor was observed while whole genome gene expression analysis evidenced regulation of many cell cycle regulated genes as well integrin and focal adhesion kinase (FAK) signalling to impact cytoskeleton dynamics, migration, invasion and metastasis.
Conclusions/Significance:
Our experiments and recently published in vivo engraftment studies with various tumour cell lines revealed the dual kinase inhibitors to be efficient in their antitumour activity.
Insights
New pyrazolo[3,4-d]pyrimidines effectively inhibit overexpressed c-Abl and c-Src kinases in multiple cancer cell lines. These dual kinase inhibitors show significant antitumour activity by inducing apoptosis and repressing key proteins involved in tumor progression.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-receptor tyrosine kinases c-Abl and c-Src are frequently overexpressed in solid human tumors.
- Inhibiting these kinases is a promising strategy for cancer treatment.
- This study investigates a novel class of pyrazolo[3,4-d]pyrimidines as potential therapeutic agents.
Purpose of the Study:
- To evaluate the effects of new pyrazolo[3,4-d]pyrimidine derivatives on various cancer cell lines.
- To elucidate the mechanism of action of these experimental drugs.
- To assess their potential as anticancer agents.
Main Methods:
- Treatment of murine lung tumor progenitor cell lines, A549, HepG2, and CaCo2 cells with pyrazolo[3,4-d]pyrimidines.
- Assays to measure kinase activity, apoptosis, cell viability, and cell cycle progression.
- Western blot analysis to confirm protein expression changes.
- Whole genome gene expression analysis.
Main Results:
- Dual kinase inhibitors potently blocked c-Abl and c-Src activity in the nanomolar range.
- Inhibitors induced apoptosis, reduced cell viability, and caused G0/G1 cell cycle arrest.
- Repression of c-Abl, c-Src, and interacting proteins (MAPK, HNRNPK, CDK1) was confirmed.
- Significant downregulation of EGFR and regulation of cell cycle, integrin, and FAK signaling pathways were observed, impacting cell migration and invasion.
Conclusions:
- The pyrazolo[3,4-d]pyrimidines demonstrated potent antitumour activity in vitro.
- Combined with in vivo studies, these dual kinase inhibitors show promise as effective anticancer therapeutics.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity